Glucagon-like Peptide 2, Control Peptide (GLP2)
Catalog No : USB-G2040-37A
417.25€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Glucagon-like Peptide 2, Control Peptide (GLP2) | ||
|---|---|---|---|
| Catalog No | USB-G2040-37A | ||
| Supplier’s Catalog No | G2040-37A | ||
| Supplier | US Biologicals | ||
| Source antigen | |||
| Reactivity | |||
| Cross reactivity | Gp Human, Mouse, Rat | ||
| Applications | |||
| Molecular weight | |||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Purified | ||
| Purity | Purified | ||
| Form | Supplied as a lyophilized powder from PBS, 0.05% sodium azide. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | Purified | ||
| Description | Synthetic peptide of corresponding to an 8aa C- terminal epitope of human GLP2, corresponding to anti-GLP2 G2040-37 which Recognizes human GLP2. Peptide is 100% conserved in mouse, rat, guinea pig and 88% in bovine. No significant sequence homology is detected with other proteins. Glucagon is a member of a multigene family comprising of Secretin, Vasoactive Intestinal Peptide (VIP), Gastric Inhibitory Peptide (GIP) and others like Glicentin and Oxyntomodulin (OXM), which differs from glucagon by C-terminal octapeptide. The glucagon precursor contains at least 3 intervening sequences that divide the protein-coding portion into 4 regions corresponding to the signal peptide and part of the N-terminal peptide, the remainder of the N-terminal peptide and glucagon, glucagon-like peptide-1 (GLP1), and GLP2. The GLP 1 & 2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crupt cell proliferation and decreased enterocyte apoptosis. The two GLP's are mainly produced in the A cells of the Islets of Langerhans in response to a drop in blood sugar concentration. GLP2, also a processed active peptide with 33aa, (chr 2q36-q37). GLP2 regulates gastric motility, gastric acid secretion, intestinal hexose transport, and increases the barrier function of the gut epithelium. It significantly enhances the surface area of the mucosal epithelium via stimulation of crypt cell proliferation. The actions of GLP2 are transduced by the GLP2 receptor, a G-protein-coupled receptor, activation of receptor signaling in heterologous cells promotes resistance to apoptotic injury in vitro, as such it may potentially be useful in treatment of injury and dysfunction of intestinal mucosal epithelium. Applications: Suitable for use in ELISA. Other applications not tested. Recommended Dilution: ELISA: 50-100ng control peptide/well using anti-GLP2 at 1:100,000. Also used for antibody blocking experiments at 5-10ug control peptide per 1ug of affinity purified IgG to confirm antibody specificity. The control peptide, because of its low mol. Wt (<3kD), is not suitable for Western. It should be used for ELISA or antibody blocking experiments (use 5-10ug control peptide per 1ug of affinity purified IgG to confirm antibody specificity Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved